N-[4-[[4-(1,3-benzoxazol-2-yl)phenyl]carbamoyl]phenyl]-1-benzofuran-2-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-[[4-(1,3-benzoxazol-2-yl)phenyl]carbamoyl]phenyl]-1-benzofuran-2-carboxamide
• 化学式: C₂₉H₁₉N₃O₄
• 分子量: 473.5
• InChiKey: ALQIZRCPSILFNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.4
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
  申请人：Shifa Biomedical Corporation

  公开号：US10899748B2

  公开（公告）日：2021-01-26

  Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

  所公开的是调节9型（PCSK9）蛋白转换酶的生理作用的化合物，以及使用此类化合物降低低密度脂蛋白胆固醇水平和/或治疗和/或预防心血管疾病（CVD）（包括治疗高胆固醇血症）的治疗方法。
• Application of PCSK9 inhibitors in the preparation of drugs for the treatment of inflammatory immune diseases
  申请人：Chen Min

  公开号：US11214625B2

  公开（公告）日：2022-01-04

  The invention belongs to the biopharmaceutical. It involves the role and mechanism of PCSK9 in inflammatory immune diseases, and the application of PCSK9 inhibitors to the preparation of drugs for the treatment of inflammatory immune diseases mediated by T cells. In particular, it involves the use of PCSK9 monoclonal antibody, PCSK9 interference RNA and PCSK9 small molecule inhibitors for treating psoriasis, atopic dermatitis, or urticaria. The invention uses psoriasis as an embodiment for the study of inflammatory and immune diseases. It is found that PCSK9 plays an important role in the treatment of inflammatory immune diseases. The PCSK9 monoclonal antibody, PCSK9 interference RNA, and PCSK9 small molecule inhibitor can be further developed for treating inflammatory immune-diseases, such as psoriasis with fewer adverse reactions, at low cost, and with good efficacy.

  本发明属于生物制药。它涉及 PCSK9 在炎症性免疫疾病中的作用和机制，以及 PCSK9 抑制剂在制备治疗由 T 细胞介导的炎症性免疫疾病药物中的应用。具体而言，本发明涉及使用 PCSK9 单克隆抗体、PCSK9 干扰 RNA 和 PCSK9 小分子抑制剂治疗银屑病、特应性皮炎或荨麻疹。本发明将银屑病作为研究炎症和免疫疾病的一个实例。研究发现，PCSK9 在炎症性免疫疾病的治疗中发挥着重要作用。可以进一步开发PCSK9单克隆抗体、PCSK9干扰RNA和PCSK9小分子抑制剂，用于治疗银屑病等炎症免疫性疾病，不良反应少，成本低，疗效好。
• ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES
  申请人：Shifa Biomedical Corporation

  公开号：EP3471714A1

  公开（公告）日：2019-04-24
• Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases
  申请人：Shifa Biomedical Corporation

  公开号：US20190270729A1

  公开（公告）日：2019-09-05

  Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
• APPLICATION OF PCSK9 INHIBITORS IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES
  申请人：CHEN Min

  公开号：US20220073647A1

  公开（公告）日：2022-03-10

  The invention belongs to the biopharmaceutical. It involves the role and mechanism of PCSK9 in inflammatory immune diseases, and the application of PCSK9 inhibitors to the preparation of drugs for the treatment of inflammatory immune diseases mediated by T cells. In particular, it involves the use of PCSK9 monoclonal antibody, PCSK9 interference RNA and PCSK9 small molecule inhibitors for treating psoriasis, atopic dermatitis, or urticaria. The invention uses psoriasis as an embodiment for the study of inflammatory and immune diseases. It is found that PCSK9 plays an important role in the treatment of inflammatory immune diseases. The PCSK9 monoclonal antibody, PCSK9 interference RNA, and PCSK9 small molecule inhibitor can be further developed for treating inflammatory immune-diseases, such as psoriasis with fewer adverse reactions, at low cost, and with good efficacy.